SCHEMBL2013660

SCHEMBL2013660

CCOC(=O)COc1ccc(O)c(C(=O)CN2Cc3cc(C(N)=S)ccc3C2=O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 4/20 0.44
ITGB3 P05106 2/20 0.43
ITGA2B P08514 2/20 0.43
HPGD P15428 4/20 0.40
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
HSD17B10 Q99714 5/20 0.36
KDM4E B2RXH2 4/20 0.36
GAA P10253 4/20 0.36
ALDH1A1 P00352 3/20 0.36
CASP1 P29466 2/20 0.36
ALOX15 P16050 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
TP53 P04637 2/20 0.35
GLA P06280 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
LMNA P02545 1/20 0.34
ALDH2 P05091 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2011122 0.93 HPGD (0.46) AOC3ITGB3ITGA2BHPGDADORA2A
SCHEMBL2006457 0.91 AOC3 (0.45) AOC3ITGB3ITGA2BHPGDADORA2B
SCHEMBL2009709 0.90 AOC3 (0.44) AOC3ITGB3ITGA2BHPGDADORA2B
SCHEMBL2007989 0.89 AOC3 (0.46) AOC3ITGB3ITGA2BHPGDHSD17B10
SCHEMBL2010451 0.89 ITGB3 (0.38) AOC3ITGB3ITGA2BHPGDKDM4E
SCHEMBL2010952 0.88 AOC3 (0.43) AOC3ITGB3ITGA2BHPGDADORA2B
SCHEMBL2012067 0.88 ITGB3 (0.42) AOC3ITGB3ITGA2BHPGDADORA2A
SCHEMBL2010431 0.88 AOC3 (0.42) AOC3ITGB3ITGA2BHPGDADORA2B
SCHEMBL3611645 0.87 ITGB3 (0.42) AOC3ITGB3ITGA2BHPGDADORA2A
SCHEMBL2010377 0.87 ITGB3 (0.42) AOC3ITGB3ITGA2BHPGDADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 AOC3 3283/4885ITGB3 169/4885ITGA2B 63/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 AOC3 3283/4885ITGB3 169/4885ITGA2B 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.